# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-30T17:19:25.822809
**Response ID:** resp_037f72c98e8eb83700697cd94e43c08191b965c853b5979f59
**Tokens:** 29319 in / 6562 out
**Response SHA256:** 0a615951880b5db8

---

FATAL ERROR 1: Data–Design Alignment (treatment timing mis-coded in placebo analysis)  
  **Location:** Appendix D.4 “Placebo RDD on Unrelated Referendums”; **Table 11** (and **Appendix A.1** note)  
  **Error:** For placebo referendums in **Feb 2016** and **Jun 2016** (and partly **Sep 2016**), the paper uses the indicator “treated by May 2017” even though **BL (in force July 2016)** and **BS (in force Jan 2017)** were not yet treated for those outcomes. That creates mechanically post-dated “treatment” for pre-treatment outcomes, so these placebo discontinuities are not interpretable as evidence about generic border differences under the intended design. This is exactly the kind of “treatment in year X, outcome in year < X” misalignment that can embarrass you in review.  
  **Fix:** Re-code treatment **separately for each referendum date** using “law in force by referendum date.” Concretely:  
  - Feb 2016 / Jun 2016: treated should be **GR, BE, AG only**; BL and BS must be control.  
  - Sep 2016: treated should include **BL** but not **BS**.  
  Then re-run the placebo RDD with the correctly dated treatment definition (and ideally the same sample construction as the main RDD; see Error 2). If you cannot do this cleanly, drop the placebo table rather than presenting invalid placebos.

FATAL ERROR 2: Internal Consistency / Completeness (robustness/diagnostics are not for the main design but are used as if they validate it)  
  **Location:** Section **6.2** (“RDD Diagnostics”), Section **6.4** (“Summary of Results”), Appendix **D.2** (Table 10), Appendix **D.4** (Table 11), plus Figures **6, 9, 10** as described in text  
  **Error:** The paper’s **main causal estimate** is explicitly the **corrected-sample, same-language border RDD** (Table 4, row 2). However, multiple “diagnostics/robustness” exercises that the text treats as supporting the main result are run on a **different running variable/sample (“pre-correction sample”, distance to union boundary)** and/or different border sets. Examples explicitly stated in the draft:  
  - Bandwidth sensitivity (Figure 9) uses the pre-correction sample.  
  - Donut RDD (Figure 10 / Table 10) uses the pre-correction sample.  
  - Placebos (Table 11) use the pre-correction sample (and also have the timing problem in Error 1).  
  Yet the narrative in 6.2/6.4 asserts these checks “support the validity of the RDD design” and “support the main finding,” which is not warranted because they are not tests of the *actual* identifying setup used for the headline estimate. A journal referee can easily call this out as “robustness not performed for the reported specification.”  
  **Fix:** Re-run *all* diagnostics/robustness checks intended to support identification **on the corrected sample construction and (for the main claim) the same-language border restriction**, i.e., the exact design that produces −5.9 pp in Table 4 row 2. At minimum:  
  - McCrary/density and covariate balance for the **same-language corrected** sample with its bandwidth (3.2 km).  
  - Bandwidth sensitivity and donut RDD for the **same-language corrected** sample.  
  - Placebos (after fixing timing per Error 1) using the **same corrected construction**.  
  If you keep the pre-correction versions for historical comparison, they must be labeled as such and you must stop using them as validation for the corrected-design estimate.

ADVISOR VERDICT: FAIL